NCT03896945: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 5 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT03896945 |
|---|---|
| Title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Negative Symptoms of Schizophrenia |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 15, 2019 |
| Completion date | May 23, 2023 |
| Required reporting date | May 23, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |